What To Know About Diabetes Prevention Programs

What to Know About Diabetes Prevention Programs

Thanks in part to the YMCA Diabetes Prevention Program, 41-year-old Erin Rothermel was able to lose 60 pounds and reduce his blood pressure, among other health improvements.
Eric Rothermel, now 41, has always been mindful of his health. A tobacco control professional at the YMCA in Harrisburg, Pennsylvania, he knows the importance of following a healthy diet, exercising, and watching your weight. But when he turned 39, he realized that some of his habits, like his waning physical activity, were beginning to catch up with him: His weight had crept up, and he could feel his energy levels plummeting.
When I weighed 282 pounds, I could feel it by the end of the day, Rothermel says. I was dragging.
Based on his weight, Rothermels colleague, who also happened to be Rothermels lifestyle coach, Megan Maurer, gave him a diabetes risk assessment questionnaire. The questionnaire showed that because of risk factors like a family history of diabetes and his body mass index (BMI) Eric was at risk of developing type 2 diabetes. She suggested that he try the YMCAs Diabetes Prevention Program (DPP) .
To be completely honest, I wasnt thrilled about it, Rothermel says of the yearlong program. I knew what to do, and I knew I could get this under control. However, I wasnt doing anything about it.
Despite his skepticism, Rothermel joined the program.
How Diabetes Prevention Programs May Help Change the Course of Your Health
While every DPP has its own distinct features, the overall aim of these programs is to help people with prediabetes avoid developing full-blown type 2 diabetes.
Th Continue reading

Rate this article

Total 1 ratings

$Impact of menopause and diabetes on atherogenic lipid profile: is it worth to analyse lipoprotein subfractions to assess cardiovascular risk in women?$

Impact of menopause and diabetes on atherogenic lipid profile: is it worth to analyse lipoprotein subfractions to assess cardiovascular risk in women?

Abstract
Cardiovascular disease is the leading cause of death in women at advanced age, who are affected a decade later compared to men. Cardiovascular risk factors in women are not properly investigated nor treated and events are frequently lethal. Both menopause and type 2 diabetes substantially increase cardiovascular risk in the female sex, promoting modifications on lipid metabolism and circulating lipoproteins. Lipoprotein subfractions suffer a shift after menopause towards a more atherogenic lipid profile, consisted of hypertriglyceridemia, lower levels of both total high density lipoprotein (HDL) and its subfraction HDL2, but also higher levels of HDL3 and small low-density lipoprotein particles. This review discusses the impact of diabetes and menopause to the lipid profile, challenges in lipoprotein subfractions determination and their potential contribution to the cardiovascular risk assessment in women. It is still unclear whether lipoprotein subfraction changes are a major driver of cardiometabolic risk and which modifications are predominant. Prospective trials with larger samples, methodological standardizations and pharmacological approaches are needed to clarify the role of lipoprotein subfractions determination on cardiovascular risk prediction and intervention planning in postmenopausal women, with or without DM.
Background
Cardiovascular disease (CVD), particularly coronary artery disease (CAD) [1], is a major cause of death in women, who develop it about 10 years later then men [2]. Traditional risk factors are present at a high frequency in individuals Continue reading

How NOT to treat type 2diabetes

Nephrologist. Special interest in type 2 diabetes reversal and intermittent fasting. Founder of Intensive Dietary Management Program.
By the mid 1990s, the landmark DCCT trial has established the paradigm of glucotoxicity, in type 1 but not in type 2 diabetes. Still euphoric from the trials success, it seemed only a matter of time before tight blood glucose control was proven beneficial in type 2 diabetes as well.
Nobody stopped to consider exactly how giving insulin to hyperinsulinemic patients was going to help. Nobody paused to consider that insulin toxicity might outweigh glucotoxicity. So, borrowing heavily from the type 1 diabetes playbook, the use of insulin is increasingly used for type 2 diabetes as well.
Over the last decade, the number of patients using insulin rose 50% as almost 1/3 of diabetic patients in the United States use some form of insulin overall. This is slightly horrifying, considering that 9095% of diabetes in the United States is T2D, where the use of insulin is highly questionable.
In particular, the priority was to reduce cardiovascular disease. While type 2 diabetes is associated with numerous complications including nerve, kidney and eye damage, the morbidity and mortality associated with cardiovascular diseases dwarfed those by an order of magnitude. Simply put, most diabetic patients died of cardiovascular disease.
The United Kingdom Prospective Diabetes study, known as the UKPDS, was going to be the study that would prove the benefits of intensive blood glucose control. Almost 4000 newly diagnosed type 2 diabetic patients were randoml Continue reading

Is broccoli a secret weapon against diabetes? Extract of the vegetable may help patients regulate their blood sugar levels

Research has found eating or drinking broccoli in the form of juice could help
Controlling diabetes is a huge expense for the NHS around 10% of its budget
Lifestyle changes in particular controlling obesity - helps stop the condition
Broccoli could be key to treating diabetes as a compound in the vegetable helps to lower blood sugar levels.
Research has found that eating or drinking broccoli in the form of juice could help stop type 2 diabetes.
Controlling diabetes is a huge expense for the NHS around 10 per cent of its total budget affecting 3.9 million people.
Lifestyle changes in particular controlling obesity - is an important way to stop the disease.
But in the short term for many, there are problems with existing drug treatments.
Research has found eating or drinking broccoli in the form of juice could stop type 2 diabetes
Metformin a blood-sugar lowering drug most commonly used for the condition -cannot be taken by around 15 per cent of sufferers because of its effect on their kidneys.
Professor Anders Rosengren, of Lund University Diabetes Centre in Sweden, said: 'Since sulforaphane has very few side effects and can easily be provided as a broccoli shake or drink - for example - it has the potential to become an important compliment to existing treatment options for type 2 diabetes.
'We will now work to make broccoli sprout extract available to produce as a functional food.'
The death sentence caused by poverty: Three-year-old Chinese boy whose head has ballooned in size will die because his parents cannot pay for life-saving surgery
He said it Continue reading

Fighting sickle cell disease using a type 2 diabetes medication

Dr. Vivien Sheehan, assistant professor of pediatrics at Baylor and Texas Childrens Cancer and Hematology Centers
Sickle cell disease and the blood disorder beta thalassemia affect more than 180,000 Americans and millions more worldwide. Both diseases can be made milder or even cured by increasing fetal hemoglobin (HbF) levels, but current treatment to ramp up HbF is limited in its effectiveness. Researchers at Baylor College of Medicine and Texas Childrens Cancer and Hematology Centers have discovered a gene, FOXO3, involved in controlling fetal hemoglobin production and were able to target the gene and turn on fetal hemoglobin levels in patient samples in the lab using the diabetes drug metformin. This offers promising new treatments the first new drug treatment for sickle cell disease in 30 years and the first ever for beta thalassemia.
It was a major breakthrough to show that a common drug already in use for type 2 diabetes could be a treatment for sickle cell disease by inducing fetal hemoglobin, a type of hemoglobin that doesnt become sickle shaped but is usually turned off in infancy, said Dr. Vivien Sheehan , assistant professor of pediatrics at Baylor and Texas Childrens Cancer and Hematology Centers and lead investigator of the research. This is an exciting example of collaborative, bench-to-bedside research that has now resulted in a clinical trial that is already enrolling patients.
Sheehan launched this research as a clinical fellow at Baylor College of Medicine in 2011 with the goal of identifying new drug targets to help sickle cell patients make more f Continue reading